Lexicon Pharmaceuticals, Inc. (LXRX) shareholders
Close on Nov 17, 2026Market cap $792.02MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Stichting Administratiekantoor Westend Joint filing with Amaury Wittouck (39.40%), Artal Participations S.a r.l. (39.40%) and 9 more | 175,156,062 | 39.40% | 13D (active) amendment | Apr 30, 2026 |
| Artal International Management S.A. Joint filing with Mr. Amaury Wittouck (36.20%), Artal Participations S.a r.l. (36.20%) and 9 more | 154,734,327 | 36.20% | 13D (active) amendment | Jan 29, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (15.00%) | 66,743,390 | 15.00% | 13G (passive) amendment | Sep 30, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (10.50%) | 38,137,535 | 10.50% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LXRX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Artal Group S.A. | 175,156,062 | 39.36% | $420.37M | +20,421,735 | 45.15% |
| FMR LLC | 51,782,045 | 11.64% | $124.28M | +6,725,707 | 0.01% |
| Siren, L.L.C. | 44,303,518 | 9.96% | $106.33M | – | 2.15% |
| Sessa Capital IM, L.P. | 18,960,836 | 4.26% | $45.51M | +1,047,875 | 0.76% |
| BlackRock, Inc. | 17,348,741 | 3.90% | $41.64M | +14,026,522 | 0.00% |
| Vanguard Capital Management LLC | 9,901,208 | 2.23% | $23.76M | +382,041 | 0.00% |
| Point72 Asset Management, L.P. | 8,251,325 | 1.85% | $19.80M | +436,719 | 0.02% |
| Geode Capital Management, LLC | 6,244,372 | 1.40% | $14.99M | +3,075,261 | 0.00% |
| State Street Corp | 4,917,769 | 1.11% | $11.80M | +3,953,731 | 0.00% |
| Vanguard Portfolio Management LLC | 2,357,749 | 0.53% | $5.66M | +1,811,149 | 0.00% |
| Northern Trust Corp | 1,968,619 | 0.44% | $4.72M | +1,473,953 | 0.00% |
| Charles Schwab Investment Management Inc | 1,956,775 | 0.44% | $4.70M | +645,477 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,634,571 | 0.37% | $3.92M | +302,287 | 0.00% |
| Citadel Advisors LLC | 1,601,182 | 0.36% | $3.84M | +506,281 | 0.00% |
| Ishara Investments LP | 1,271,000 | 0.29% | $3.05M | +369,000 | 2.24% |
| Millennium Management LLC | 1,134,229 | 0.25% | $2.72M | −3,810,502 | 0.00% |
| Renaissance Technologies LLC | 1,127,000 | 0.25% | $2.70M | −473,500 | 0.00% |
| Mackenzie Financial Corp | 963,354 | 0.22% | $2.31M | +190,677 | 0.00% |
| ADAR1 Capital Management, LLC | 750,000 | 0.17% | $1.80M | – | 0.08% |
| Susquehanna International Group, Llp | 696,776 | 0.16% | $1.67M | −1,424,388 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 149 | 365M | 81.9% | 45 / 36 | 36 / 30 | 61M | 20M |
| Q1 2026 | 136 | 323M | 72.7% | 31 / 41 | 26 / 15 | 78M | 3M |
| Q4 2025 | 125 | 260M | 58.5% | 23 / 28 | 41 / 17 | 12M | 6M |
| Q3 2025 | 123 | 255M | 57.3% | 18 / 26 | 42 / 17 | 9M | 11M |
| Q2 2025 | 123 | 257M | 57.8% | 29 / 31 | 36 / 33 | 16M | 25M |
| Q1 2025 | 127 | 266M | 59.7% | 31 / 34 | 32 / 29 | 11M | 42M |
| Q4 2024 | 127 | 298M | 66.9% | 25 / 45 | 24 / 34 | 29M | 20M |
| Q3 2024 | 137 | 289M | 64.9% | 26 / 46 | 21 / 14 | 74M | 57M |
| Q2 2024 | 127 | 281M | 63.2% | 26 / 48 | 22 / 17 | 114M | 6M |
| Q1 2024 | 118 | 173M | 39.0% | 33 / 31 | 31 / 20 | 22M | 36M |
| Q4 2023 | 106 | 187M | 42.0% | 25 / 30 | 24 / 31 | 14M | 16M |
| Q3 2023 | 112 | 189M | 42.4% | 11 / 45 | 30 / 21 | 5M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
72 funds held LXRX in Q2 2026, 42% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of LXRX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 16,542,000 | 3.72% | $36.06M | 0.04% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 7,083,651 | 1.59% | $17.00M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 6,209,944 | 1.40% | $14.90M | 0.02% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 4,887,306 | 1.10% | $10.65M | 0.04% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 3,977,693 | 0.89% | $8.67M | 0.04% | May 31, 2026 |
| Fidelity Small Cap Index Fund | 2,722,989 | 0.61% | $6.29M | 0.02% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 2,567,310 | 0.58% | $6.16M | 0.01% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 2,278,291 | 0.51% | $5.47M | 0.04% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 1,121,988 | 0.25% | $2.69M | 0.63% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,112,834 | 0.25% | $2.43M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 1,032,223 | 0.23% | $2.25M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 835,530 | 0.19% | $2.01M | 0.13% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 604,413 | 0.14% | $1.40M | 0.02% | Jul 31, 2026 |
| Vanguard Health Care Index Fund | 544,199 | 0.12% | $1.19M | 0.01% | May 31, 2026 |
| Select Biotechnology Portfolio | 515,300 | 0.12% | $1.12M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Michael Exton | Chief Executive Officer, Director | 328,496 | 0.07% | Nov 9, 2026 |
| Brian T. Crum | SVP, General Counsel & Secr. | 330,201 | 0.07% | Mar 3, 2026 |
| Lisa DeFrancesco | SVP, IR and Corp Comm | 40,251 | 0.01% | Mar 3, 2026 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 67,090 | 0.02% | Mar 3, 2026 |
| Suma Gopinathan | SVP, Discovery | 88,520 | 0.02% | Mar 3, 2026 |
| Scott M. Coiante | SVP, Chief Financial Officer | 105,356 | 0.02% | Mar 3, 2026 |
| Craig B. Granowitz | SVP, Chief Medical Officer | 432,528 | 0.10% | Mar 3, 2026 |
| Wendy McDermott | SVP, Human Resources | 277,945 | 0.06% | Mar 3, 2026 |
| Kristen Alexander | VP, Finance and Accounting | 76,368 | 0.02% | Mar 3, 2025 |
| Alan J. Main | EVP, Innov & Chem Sciences | 281,391 | 0.06% | Mar 3, 2025 |
| Brian Corrigan | SVP, Regulatory & QA | – | – | Feb 18, 2025 |
| Diane E. Sullivan | Director | 126,122 | 0.03% | Jun 4, 2026 |
| Judith L. Swain | Director | 174,486 | 0.04% | Jun 4, 2026 |
| Ivan Cheung | Director | 89,312 | 0.02% | Jun 4, 2026 |
| Sam L. Barker | Director | 248,771 | 0.06% | Jun 4, 2026 |
| Raymond Debbane | Director | 51,750,221 | 11.63% | Jun 4, 2026 |
| Philippe Amouyal | Director | 374,486 | 0.08% | Jun 4, 2026 |
| Christopher J. Sobecki | Director | 293,177 | 0.07% | Jun 4, 2026 |
| S.A. Westend | Director, 10% owner | 3,333,376 | 0.75% | May 8, 2026 |
| Administratiekantoor Westend Stichting | Director, 10% owner | 1,150,922 | 0.26% | May 8, 2026 |
| International Management S.A. Artal | Director, 10% owner | 3,006,678 | 0.68% | May 8, 2026 |
| International S.C.A. Artal | Director, 10% owner | 408,435 | 0.09% | May 8, 2026 |
| Group S.A. Artal | Director, 10% owner | 367,145 | 0.08% | May 8, 2026 |
| Amaury Wittouck | Director, 10% owner | 3,516,214 | 0.79% | May 8, 2026 |
| Participations S.a r.l. Artal | Director, 10% owner | 311,336,543 | 69.97% | May 8, 2026 |
| Life Sci Master GP LLC Avicenna | Director, 10% owner | 1,538,462 | 0.35% | Feb 12, 2026 |
| Life Sci Master Fund LP Avicenna | Director, 10% owner | – | – | Feb 12, 2026 |
| Invus Global Management, LLC | Director, 10% owner | – | – | Feb 4, 2026 |
| Siren, L.L.C. | Director, 10% owner | 35,402,689 | 7.96% | Feb 4, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Exton Chief Executive Officer, Director | Nov 6, 2026 | Buy | +30,064 | $1.66 | $50.00K | 328,496 |
| Diane E. Sullivan Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 126,122 |
| Ivan Cheung Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 89,312 |
| Raymond Debbane Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 1,995,498 |
| Sam L. Barker Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 213,771 |
| Judith L. Swain Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 174,486 |
| Christopher J. Sobecki Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 293,177 |
| Philippe Amouyal Director | Jun 3, 2026 | Option exercise | +89,312 | – | – | 374,486 |
| Participations S.a r.l. Artal Director, 10% owner | Apr 30, 2026 | Option exercise | +20,421,735 | – | – | 175,156,062 |
| Suma Gopinathan SVP, Discovery | Feb 28, 2026 | Option exercise | +14,000 | – | – | 88,520 |
| Suma Gopinathan SVP, Discovery | Feb 28, 2026 | Option exercise | +20,310 | – | – | 108,830 |
| Suma Gopinathan SVP, Discovery | Feb 28, 2026 | Tax withholding | −24,338 | $1.47 | $35.78K | 150,132 |
| Suma Gopinathan SVP, Discovery | Feb 28, 2026 | Option exercise | +65,640 | – | – | 174,470 |
| Scott M. Coiante SVP, Chief Financial Officer | Feb 28, 2026 | Tax withholding | −54,881 | $1.47 | $80.68K | 105,356 |
| Scott M. Coiante SVP, Chief Financial Officer | Feb 28, 2026 | Option exercise | +160,237 | – | – | 160,237 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2026 | Option exercise | +24,674 | – | – | 40,251 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2026 | Option exercise | +128,190 | – | – | 168,441 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2026 | Tax withholding | −74,572 | $1.47 | $109.62K | 93,869 |
| Rachel Yap Martens SVP, Partnerships & Corp Strat | Feb 28, 2026 | Option exercise | +67,090 | – | – | 67,090 |
| Rachel Yap Martens SVP, Partnerships & Corp Strat | Feb 28, 2026 | Tax withholding | −35,826 | $1.47 | $52.66K | 31,264 |
| Michael Exton Chief Executive Officer, Director | Feb 28, 2026 | Option exercise | +503,263 | – | – | 503,263 |
| Michael Exton Chief Executive Officer, Director | Feb 28, 2026 | Tax withholding | −204,831 | $1.47 | $301.10K | 298,432 |
| Wendy McDermott SVP, Human Resources | Feb 28, 2026 | Tax withholding | −68,107 | $1.47 | $100.12K | 277,945 |
| Wendy McDermott SVP, Human Resources | Feb 28, 2026 | Option exercise | +144,393 | – | – | 346,052 |
| Wendy McDermott SVP, Human Resources | Feb 28, 2026 | Option exercise | +27,697 | – | – | 149,343 |
| Wendy McDermott SVP, Human Resources | Feb 28, 2026 | Option exercise | +52,316 | – | – | 201,659 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2026 | Option exercise | +69,386 | – | – | 330,201 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2026 | Tax withholding | −105,019 | $1.47 | $154.38K | 428,802 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2026 | Option exercise | +33,457 | – | – | 363,658 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2026 | Option exercise | +170,163 | – | – | 533,821 |
| Craig B. Granowitz SVP, Chief Medical Officer | Feb 28, 2026 | Option exercise | +202,260 | – | – | 432,528 |
| Craig B. Granowitz SVP, Chief Medical Officer | Feb 28, 2026 | Tax withholding | −109,098 | $1.47 | $160.37K | 323,430 |
| Craig B. Granowitz SVP, Chief Medical Officer | Feb 28, 2026 | Option exercise | +74,226 | – | – | 230,268 |
| Craig B. Granowitz SVP, Chief Medical Officer | Feb 28, 2026 | Option exercise | +35,790 | – | – | 156,042 |
| Raymond Debbane Director | Feb 25, 2026 | Buy | +2,000 | $1.49 | $2.98K | 1,906,186 |
| Raymond Debbane Director | Feb 23, 2026 | Buy | +100,000 | $1.47 | $147.00K | 1,904,186 |
| Raymond Debbane Director | Feb 20, 2026 | Buy | +100,000 | $1.48 | $148.00K | 1,804,186 |
| Raymond Debbane Director | Feb 19, 2026 | Buy | +50,000 | $1.44 | $72.00K | 1,704,186 |
| Raymond Debbane Director | Feb 18, 2026 | Buy | +133,688 | $1.32 | $176.47K | 1,654,186 |
| International S.C.A. Artal Director, 10% owner | Feb 17, 2026 | Award | +41,289.58 | $65.00 | $2.68M | 408,435 |
| Raymond Debbane Director | Feb 17, 2026 | Buy | +76,857 | $1.31 | $100.68K | 1,520,498 |
| Raymond Debbane Director | Feb 13, 2026 | Buy | +57,952 | $1.31 | $75.92K | 1,443,641 |
| Group S.A. Artal Director, 10% owner | Feb 2, 2026 | Award | +367,145.12 | $65.00 | $23.86M | 367,145 |
| Group S.A. Artal Director, 10% owner | Feb 2, 2026 | Award | +18,553,846 | $1.30 | $24.12M | 154,734,327 |
| Group S.A. Artal Director, 10% owner | Feb 2, 2026 | Award | +3,846,154 | $1.30 | $5.00M | 7,362,368 |
| Group S.A. Artal Director, 10% owner | Feb 2, 2026 | Buy | +1,538,462 | $1.30 | $2.00M | 1,538,462 |
| Christopher J. Sobecki Director | May 13, 2025 | Option exercise | +36,810 | – | – | 203,865 |
| Sam L. Barker Director | May 13, 2025 | Option exercise | +36,810 | – | – | 124,459 |
| Judith L. Swain Director | May 13, 2025 | Option exercise | +36,810 | – | – | 85,174 |
| Diane E. Sullivan Director | May 13, 2025 | Option exercise | +36,810 | – | – | 36,810 |
| Philippe Amouyal Director | May 13, 2025 | Option exercise | +36,810 | – | – | 285,174 |
| Raymond Debbane Director | May 13, 2025 | Option exercise | +36,810 | – | – | 1,385,689 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2025 | Tax withholding | −45,622 | $0.67 | $30.57K | 260,815 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2025 | Option exercise | +69,387 | – | – | 306,437 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2025 | Option exercise | +33,456 | – | – | 237,050 |
| Brian T. Crum SVP, General Counsel & Secr. | Feb 28, 2025 | Option exercise | +26,097 | – | – | 203,594 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2025 | Option exercise | +24,673 | – | – | 24,673 |
| Lisa DeFrancesco SVP, IR and Corp Comm | Feb 28, 2025 | Tax withholding | −9,096 | $0.67 | $6.09K | 15,577 |
| Alan J. Main EVP, Innov & Chem Sciences | Feb 28, 2025 | Option exercise | +25,667 | – | – | 281,391 |
| Alan J. Main EVP, Innov & Chem Sciences | Feb 28, 2025 | Option exercise | +32,904 | – | – | 314,295 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Lexicon Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 124,382 shares on Aug 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lonnel Coats Former Affiliate | Aug 15, 2024 | 300,000 | $480.00K | Aug 15, 2024 | Restricted Stock Lapse - see remarks |
| Seth Kiernan Former Affiliate | Jul 12, 2023 | 19,000 | $43.89K | Jul 12, 2023 | Restricted Stock Lapse |
See a number that looks wrong?